Ketamine Science
Exploring the latest research on ketamine treatments.
Scientific Publications
Systematic Review on Optimal Ketamine Dose in TRD (Mayo Clinic, 2024): Supports low and standard-dose IV ketamine (0.2–0.5 mg/kg) are effective in depression, including comorbid PTSD, with no greater efficacy at higher doses. Intranasal esketamine at 56–84 mg also improves symptoms.
Intranasal Esketamine for TRD with PTSD (2022): Twice-weekly low-dose IN esketamine led to sustained improvements in comorbid treatment-resistant depression and PTSD, with most patients responding without serious adverse reactions.
Intranasal Racemic Ketamine in TRD (2025): Research on safety, dosing, and efficacy of daily or repeated-dose intranasal racemic ketamine for treatment-resistant depression—often comorbid with PTSD—shows favorable results.
Intranasal (S)-Ketamine for Veterans with TRD and PTSD: Outcomes for intranasal (S)-ketamine in veterans show improvement in both depression and PTSD, supporting its role in refractory cases at low, repeated doses.
Single IV Ketamine Infusion for Rapid PTSD Symptom Relief (Mount Sinai, 2014): A double-blind, crossover trial using low-dose IV (0.5 mg/kg) ketamine gave significant symptom reduction in PTSD and comorbid depression within 24 hours.
Ketamine NMDA Receptor Blocker for Depression/PTSD (2022): Reviews efficacy and safety of low-dose ketamine as NMDA antagonist in depression and PTSD—emphasizes rapid onset and application of low-dose protocols.
Effectiveness of Ketamine for PTSD (Systematic Review, 2024): Analyzes various studies, most using low-dose infusions, and identifies ketamine as a promising intervention for PTSD, pending further research.
Intensive 7-day Treatment for PTSD Using Ketamine and Prolonged Exposure: Examines combining ketamine infusions with exposure therapy for rapid PTSD relief—protocol involves daily administration.
Ketamine for PTSD Clinical Trial: Single IV dose (0.5 mg/kg) administered in veterans with PTSD, resulting in rapid symptom relief and few side effects.
New Discoveries in Ketamine for PTSD: Highlights new mechanisms and dosing considerations for ketamine in chronic PTSD; many studies cited used low, repeated doses.
Long-term Neural Changes after Ketamine for Depression: Patients with major depression and some PTSD comorbidity showed lasting brain changes after ketamine (various dosing/frequency).
Ketamine in Multiple TRD Inpatients: Hospital-based study found rapid and notable symptom improvements in severe depression and PTSD—summary includes multi-dose, multi-protocol approaches.
Ketamine as a Treatment for PTSD (Clinical Trial): Compared ketamine infusion versus placebo for acute symptom reduction in PTSD.
Ketamine for Major Depression (Lancet Review, 2023): Review emphasizes rapid antidepressant effects of ketamine, including in PTSD populations, but doesn’t always specify dosing intervals.
New Findings on Ketamine for PTSD and Depression (Mount Sinai, 2022): Intranasal ketamine spray demonstrated rapid symptom relief for both depression and PTSD, supporting its use in outpatient and daily protocols.
Contact Us
Get in touch for inquiries or support.
admin@newdaythera.com